| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.58B | 2.59B | 2.74B | 2.59B | 2.48B | 2.46B |
| Gross Profit | 1.01B | 997.69M | 1.09B | 1.08B | 1.02B | 1.01B |
| EBITDA | 336.48M | 339.66M | 412.09M | 305.18M | 293.42M | 240.97M |
| Net Income | 111.62M | 100.21M | 157.94M | 100.66M | 120.93M | 71.68M |
Balance Sheet | ||||||
| Total Assets | 2.92B | 2.94B | 2.98B | 3.47B | 3.71B | 3.66B |
| Cash, Cash Equivalents and Short-Term Investments | 1.14B | 1.26B | 1.21B | 1.77B | 1.73B | 1.57B |
| Total Debt | 132.26M | 178.52M | 240.20M | 503.88M | 589.56M | 673.24M |
| Total Liabilities | 916.71M | 992.17M | 1.13B | 1.29B | 1.40B | 1.46B |
| Stockholders Equity | 2.00B | 1.95B | 1.84B | 2.18B | 2.32B | 2.19B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 89.28M | 245.53M | 137.27M | 235.94M | -65.91M |
| Operating Cash Flow | 0.00 | 230.29M | 339.74M | 253.20M | 346.66M | 70.00M |
| Investing Cash Flow | 0.00 | -113.00M | -135.71M | 112.32M | -113.39M | -134.28M |
| Financing Cash Flow | 0.00 | -67.92M | -760.62M | -326.80M | -81.05M | 146.21M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥2.78B | 15.63 | ― | 2.23% | -2.87% | 4.31% | |
73 Outperform | ¥2.54B | 15.93 | ― | 1.59% | 2.07% | 11.34% | |
65 Neutral | ¥2.45B | 10.51 | ― | 2.71% | -17.18% | -11.43% | |
62 Neutral | ¥1.56B | 25.69 | ― | ― | 5.17% | ― | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
60 Neutral | ¥1.73B | 9.53 | ― | ― | -10.89% | ― | |
49 Neutral | ¥1.78B | 11.74 | ― | ― | 8.27% | -295.89% |
SCAT Inc. has revised its consolidated earnings forecast for the fiscal year ending October 2025 due to significant impacts on its Nursing care services business. The company has experienced a decline in facility utilization rates, leading to a decrease in segment sales and profits. Despite these challenges, SCAT Inc. maintains its year-end dividend forecast unchanged.
The most recent analyst rating on (JP:3974) stock is a Buy with a Yen534.00 price target. To see the full list of analyst forecasts on SCAT Inc. stock, see the JP:3974 Stock Forecast page.
SCAT Inc. reported a slight decline in net sales for the nine months ending July 31, 2025, but saw significant improvements in operating and ordinary profits, indicating a positive trend in operational efficiency. The company also announced a plan to distribute treasury shares, effectively increasing dividends by 10%, which reflects a strategic move to enhance shareholder returns and potentially strengthen market confidence.
The most recent analyst rating on (JP:3974) stock is a Buy with a Yen534.00 price target. To see the full list of analyst forecasts on SCAT Inc. stock, see the JP:3974 Stock Forecast page.
SCAT Inc. announced a revision to its dividend forecast, deciding to allocate treasury shares free of charge at a ratio of 0.1 shares for each common share, effectively increasing dividends by 10%. This decision reflects the company’s commitment to returning profits to shareholders and is based on steady business performance as the fiscal year ending October 2025 progresses.
The most recent analyst rating on (JP:3974) stock is a Buy with a Yen534.00 price target. To see the full list of analyst forecasts on SCAT Inc. stock, see the JP:3974 Stock Forecast page.
SCAT Inc. announced a gratis allotment of shares, aiming to increase liquidity and return profits to shareholders by distributing treasury stock. This move is part of their strategy to comply with listing maintenance standards and will not affect the company’s capital or forecasted dividends, effectively increasing dividends by 10%.
The most recent analyst rating on (JP:3974) stock is a Buy with a Yen534.00 price target. To see the full list of analyst forecasts on SCAT Inc. stock, see the JP:3974 Stock Forecast page.